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Effects of Bilberry and Oat intake on lipids,
inflammation and exercise capacity after
Acute Myocardial Infarction (BIOAMI): study
protocol for a randomized, double-blind,
placebo-controlled trial
Cecilia Bergh1* , Rikard Landberg2,3, Kristina Andersson4,5, Lovisa Heyman-Lindén6,7, Ana Rascón5,8,
Anders Magnuson1, Payam Khalili9, Amra Kåregren10, Johan Nilsson3, Carlo Pirazzi11, David Erlinge12 and
Ole Fröbert13
Abstract
Background: Bilberries from Sweden, rich in polyphenols, have shown cholesterol-lowering effects in small studies,
and the cholesterol-lowering properties of oats, with abundant beta-glucans and potentially bioactive
phytochemicals, are well established. Both may provide cardiometabolic benefits following acute myocardial
infarction (AMI), but large studies of adequate statistical power and appropriate duration are needed to confirm
clinically relevant treatment effects. No previous study has evaluated the potential additive or synergistic effects of
bilberry combined with oats on cardiometabolic risk factors. Our primary objective is to assess cardioprotective
effects of diet supplementation with dried bilberry or with bioprocessed oat bran, with a secondary explorative
objective of assessing their combination, compared with a neutral isocaloric reference supplement, initiated within
5 days following percutaneous coronary intervention (PCI) for AMI.
Methods: The effects of Bilberry and Oat intake on lipids, inflammation and exercise capacity after Acute Myocardial
Infarction (BIOAMI) trial is a double-blind, randomized, placebo-controlled clinical trial. A total of 900 patients will be
randomized post-PCI to one of four dietary intervention arms. After randomization, subjects will receive beverages
with bilberry powder (active), beverages with high-fiber bioprocessed oat bran (active), beverages with bilberry and
oats combined (active), or reference beverages containing no active bilberry or active oats, for consumption twice
daily during a 3-month intervention. The primary endpoint is the difference in LDL cholesterol change between the
intervention groups after 3 months. The major secondary endpoint is exercise capacity at 3 months. Other
secondary endpoints include plasma concentrations of biochemical markers of inflammation, metabolomics, and
(Continued on next page)
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: cecilia.bergh@oru.se
1Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro
University, 701 85 Örebro, Sweden
Full list of author information is available at the end of the article
Bergh et al. Trials          (2021) 22:338 
https://doi.org/10.1186/s13063-021-05287-5
(Continued from previous page)
gut microbiota composition after 3 months.
Discussion: Controlling hyperlipidemia and inflammation is critical to preventing new cardiovascular events, but
novel pharmacological treatments for these conditions are expensive and associated with negative side effects. If
bilberry and/or oat, in addition to standard medical therapy, can lower LDL cholesterol and inflammation more
than standard therapy alone, this could be a cost-effective and safe dietary strategy for secondary prevention after
AMI.
Trial registration: ClinicalTrials.gov NCT03620266. Registered on August 8, 2018.
Keywords: Anthocyanin, Anthocyanin-derived phenolic acid metabolites, Bilberry, Cholesterol, Diet therapy, Exercise
test, Inflammation, Myocardial infarction
Background
Cardiovascular disease (CVD) is a leading cause of death
and disability globally. Dyslipidemia is a major modifi-
able risk factor for the development of atherosclerotic
plaques [1]. Systemic inflammation also plays a central
role in the atherosclerotic process from initiation
through progression and rupture of plaques [2, 3]. Ob-
servational studies suggest that the risk of acute myocar-
dial infarction (AMI) in persons with hyperlipidemia is
three times that of the population with normal lipid sta-
tus. A reduction in serum cholesterol is strongly associ-
ated with a reduction in CVD risk [4, 5]. Secondary
prevention after AMI has improved in recent decades,
but readmissions and death following AMI remain im-
portant challenges. Although new lipid-lowering medica-
tions are effective in reducing low-density lipoprotein
(LDL) cholesterol levels, clinical guidelines advocate
addition of non-statin agents [6], but their cost/efficacy
is debatable even in high-risk patients [7].
From a public health perspective, lifestyle modifica-
tion, including dietary changes, is considered a first step
in controlling and treating CVD risk factors [8]. How-
ever, patients at highest risk of premature death, AMI,
and re-hospitalization are those with known CVD [9].
Consequently, international guidelines recommend sec-
ondary prevention strategies to reduce subsequent car-
diovascular risk, such as evidence-based pharmacological
therapy and adherence to diet and physical activity regi-
mens [10]. Studies have shown positive effects on car-
diovascular risk factors of a Nordic diet, in which berries
and oats are important elements [11, 12]. However, food
supplement clinical trials that include subjects with overt
disease are scarce, and there is a need for well-planned
and well-executed controlled intervention studies of suf-
ficient size and duration to provide a firm evidence base
for dietary guidance in both healthy individuals and
those suffering from heart disease [13–15].
A meta-analysis of more than 50 clinical trials con-
cluded that oats can lower LDL cholesterol by 5–8%
[16], and subsequent data suggest other anti-atherogenic
properties of oats, including reducing inflammation and
oxidative stress [17]. Recent studies indicate that bil-
berries from Sweden, rich in polyphenols and anthocya-
nins, may have direct or indirect positive effects on
cardiovascular risk factors [13, 18, 19]. It has been sug-
gested that consumption of the anthocyanins present in
bilberries may reduce risk of death from CVD [20–22],
have beneficial effects on platelet function, increase
high-density lipoprotein (HDL) cholesterol [23, 24], and
improve exercise tolerance [25, 26]. The mechanisms of
action of berries are likely to be different from those of
oats, potentially providing additive or synergistic benefi-
cial effects. We recently conducted a small open-label
randomized clinical trial of bilberry supplementation in
patients post-AMI receiving high-dose statin treatment
and found significant beneficial effects on lipid profile
and exercise capacity in patients receiving bilberry sup-
plementation [27]. We are proceeding to conduct a
large, randomized, placebo-controlled clinical trial to as-
sess clinical impact.
Methods
Study design, hypotheses, and primary and secondary
endpoints
The effects of Bilberry and Oat intake on lipids, inflam-
mation and exercise capacity after Acute Myocardial In-
farction (BIOAMI) trial is a prospective, randomized,
double-blind, placebo-controlled multicenter trial in pa-
tients post-AMI. The primary objective is to assess dif-
ferences in LDL cholesterol change among treatments
after 3 months of a diet supplemented with a beverage
containing either dried bilberry or bioprocessed oat bran
compared with a neutral isocaloric reference drink, initi-
ated within 5 days following percutaneous coronary
intervention (PCI) for AMI. A secondary objective is to
assess the combination of bilberries and oats compared
with the reference drink. We hypothesize that standard
medical therapy supplemented with either dried bil-
berries or bioprocessed oat bran post-AMI will show a
more beneficial effect on LDL cholesterol than medical
therapy alone after 3 months. Additional secondary ob-
jectives are to determine effects on exercise capacity,
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biomarkers of inflammation and other biochemical
markers, resting heart rate, blood pressure, and left ven-
tricular systolic function (Table 1). We will also employ
untargeted metabolomics to exploratively assess alter-
ations in endogenous and exposome-related metabolites
and effects on gut microbiota composition and activity.
These exploratory analyses will allow us to investigate
the extent to which gut microbiota composition and ac-
tivity differs between responders and non-responders to
the interventions. At 1-year following randomization, we
will exploratively assess clinical endpoints in all random-
ized patients using data from the Swedish Coronary
Angiography and Angioplasty Registry (SCAAR) with re-
spect to death, new AMI, and new unplanned
revascularization.
Study population and patient selection
Subjects in this multicenter study will be recruited from
among patients referred to Sahlgrenska University Hos-
pital Gothenburg, Umeå University Hospital, Lund Uni-
versity Hospital, Västerås general hospital, Karlstad
general hospital, and Örebro University Hospital for cor-
onary angiography/PCI due to ST-segment elevation
myocardial infarction (STEMI) or non-ST-segment ele-
vation myocardial infarction (NSTEMI). STEMI is de-
fined as chest pain suggestive of myocardial ischemia for
at least 30 min prior to hospital admission with time
from onset of symptoms less than 24 h, an ECG with
new ST-segment elevation in two or more contiguous
leads of ≥ 0.2 mV in leads V2–V3 and/or ≥ 0.1 mV in
other leads, or a probable new-onset left bundle branch
block. NSTEMI is defined as a combination of onset of
symptoms such as central chest pain or aggravated an-
gina pectoris, with or without ECG changes, with ST-
segment depression or an inverted T-wave and rise and/
or fall of troponin-T or troponin-I above the established
margin of an AMI. Study inclusion and exclusion criteria
are defined in Table 2.
Randomization
Potential trial participants will receive written informa-
tion of the study, and they will receive oral information
by medical doctors participating in the study. Informed
consent shall be obtained by a Good Clinical Practice-
qualified medical doctor or research nurse participating
in the study. After providing written informed consent,
patients who fulfill inclusion criteria and with no exclu-
sion criteria will be randomized according to a
computer-generated random-number sequence. Block
randomization is performed in a 1:1:1:1 fashion stratified
by study center (Fig. 1). The study will be using SMAR
T-TRIAL® (MEDEI ApS, Aalborg, Denmark), a com-
bined password-protected web-based randomization
module and eCRF, in each participating hospital, in
order to keep the data management and the statistician
blind against the study condition as long as the data
bank is open. The randomization list remains with
SMART-TRIAL for the whole duration of the study.
Thus, randomization will be conducted without any in-
fluence of the principal investigators, raters or therapists.
Patients, investigators, and all medical staff will be
blinded to allocation.
All randomized patients will receive standard medical
and interventional treatment for AMI, including atorva-
statin at a daily dose of 80 mg. The regimen for enrol-
ment, data collection, interventions, and assessments of
the trial is further shown in Fig. 2.
Dietary intervention
Subjects will be randomized to one of the four dietary
intervention arms initiated within 5 days post-PCI and
continued for 3 months. After randomization, subjects
will receive beverages with bilberry powder (active), bev-
erages with high-fiber bioprocessed oat bran (active),
beverages with bilberry and oats combined (active), or
reference beverages containing no active bilberry or ac-
tive oats, for consumption twice daily (160 kcal/day).
The beverages will be balanced to ensure isocaloric
conditions. Intake twice a day is considered appropriate
given the relatively short elimination half-life of
Table 1 Primary and secondary endpoints
Primary endpoint
• LDL-C cholesterol
Major secondary endpoint
• Symptom-limited bicycle ergometer test (Watts and estimated
VO2max)
Other secondary endpoints
• Dynamic unilateral heel-lift and unilateral shoulder-flexion tests (n)
• Self-reported activity level (levels 1–6, days/week)
• Fasting lipid levels (TC, HDL-C, TGA, small dense LDL-C, apo A, apo B,
Lp(a), oxidized LDL)
• Fasting insulin, c-peptide, creatinine, glucose, cystatin C
• HbA1c, hs-CRP, NT-proBNP, troponin-I, IL-6
• Resting heart rate and blood pressure
• Left ventricular systolic function
• Untargeted plasma metabolome
• Gut microbiota composition
Table 2 Inclusion and exclusion criteria
Inclusion criteria
• STEMI or NSTEMI
• Completed coronary angiography/PCI
• Male and female subjects ≥ 18 years
• Allocated to atorvastatin at a daily dose of 80 mg
• Written informed consent
Exclusion criteria
• Emergency coronary artery bypass grafting
• < 18 years of age
• LDL cholesterol < 2.0 mmol/L
• Daily intake or the intent to initiate daily intake of bilberry in any form
or daily intake of > 15 g of oatmeal or equivalent
• Previous randomization in the BIOAMI trial
• Inability to provide informed consent
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anthocyanins which are believed to be important for the
hypothesized effect from bilberries. The study products
are under development by food scientists at Glucanova
(Lund, Sweden) in collaboration with Chalmers Univer-
sity of Technology, Gothenburg, Sweden. Dried bilberry
powder is provided by Immun (Skellefteå, Sweden). The
oat bran will be bioprocessed to enable production of a
palatable oat bran drink. The daily dose of oat bran will
be 50 g, providing approximately 9.5 g dietary fiber of
which 5 g beta-glucans, as well as abundant potentially
bioactive phytochemicals, such as the oat-specific poly-
phenolic avenanthramides. The daily dose of the active
bilberry product will contain 40 g dried bilberry powder,
equal to approximately 480 g of fresh berries. Bilberry
powder contains multiple anthocyanins and other poly-
phenols [27], the levels of the specific batches used in
the present study will be analyzed in the intervention
products and reported at a later date. The quantity of
bioprocessed oat bran and bilberry powder in the com-
bined study product will be 50% that of the separate
supplements. The four study products are designed with
similar texture and to look and taste as if they contain
both bilberries and liquid oats, to enable double blind-
ing. The reference product is based on starch, collagen,
corn oil, sucrose, and citric acid. Small amounts of
starch, collagen and corn oil were also added to the
dried bilberry drink and the bilberry + oats drink to en-
sure isocaloric conditions as well as similar nutrient pro-
files and sensory properties (Table 3). Subjects will be
instructed not to consume foods containing bilberry
other than the intervention products, and no more than
15 g of oatmeal, or the equivalent, per day, during the
intervention. Dietary advice according to routine treat-
ment after AMI will be given to all study subjects.
Examinations and blood tests
Subjects will be assessed at baseline, as inpatients, and at
3-month follow-up as outpatients. Examinations and
samples will be collected as follows.
Blood and fecal samples
Venous blood samples will be collected at baseline and
during intervention week 12. The blood samples will be
centrifuged immediately and stored at – 80 °C pending
further analyses. Fasting lipid profile [low-density lipo-
protein cholesterol (LDL-C); total cholesterol (TC);
high-density lipoprotein cholesterol (HDL-C); triglycer-
ides (TG); small dense low-density lipoprotein (sdLDL);
oxidized LDL; apolipoprotein A (apo A); apolipoprotein
B (apo B); lipoprotein(a) (lp[a]); inflammatory markers
high-sensitivity C-reactive protein (hs-CRP) and inter-
leukin 6 (IL-6); fasting glucose; insulin; creatinine; cysta-
tin C, C-peptide; glycosylated hemoglobin (HbA1c); and
the heart function markers troponin-I and N-terminal
pro b-type natriuretic peptide (NT-proBNP)] will be
analyzed.
Analysis of blood samples will be conducted to assess
diet compliance based on the presumption that the con-
centrations of phenolic acid derivatives will be higher in
the bilberry group and avenanthramides and/or aveno-
cosides higher in the oat and combined bilberry/oat
groups compared to the reference group [27]. Phenolic
acid derivative components associated with bilberry con-
sumption [28] and avenanthramides associated with oats
Fig. 1 Flowchart of study design. AMI, acute myocardial infarction; PCI, percutaneous coronary intervention
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will be analyzed by a validated method combining liquid
chromatography with mass spectrometry [29, 30].
Fecal samples will be collected at baseline and during
intervention week 12. All samples will be processed and
stored for metabolomics and microbiome analyses using
a fecal collection kit. For metabolomics and microbiome
testing, plasma and fecal samples will be collected pre-
and post-intervention and stored for untargeted metabo-
lomics and microbiota analysis at Chalmers University
in Gothenburg, Sweden. Plasma samples will be proc-
essed and analyzed in four modes (reverse phase/HILIC
chromatography in positive/negative ionization modes,
Fig. 2 SPIRIT figure of the trial procedure including enrolment, data collection, intervention, and assessments
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respectively) on an LC-QTOF-MS instrument according
to an established protocol [31, 32]. This will ensure the
most comprehensive collection of endogenous and
exposome-related metabolites. Gut microbiome will be
analyzed by sequencing 16S rRNA amplicons using Illu-
mina MiSeq. Data analysis strategies such as partial least
squares (PLS) and random forest will be used to identify
metabolites and microbiota that differ with treatment, as
well as to detect metabolite and bacterial composition
that may be related to high versus low responders to
LDL-lowering treatment [33]. All analyses will be per-
formed blinded, without knowledge of clinical diagnosis
or randomization.
Transthoracic echocardiography
Baseline left ventricular systolic function, expressed as
global ejection fraction in percent according to the bi-
plane Simpson method, will be evaluated by echocardi-
ography by the discharging physician. The procedure
will be repeated after 3 months by an experienced echo-
cardiography technician blinded to results of the initial
examinations. The physician and the technician will be
blinded to the intervention group.
Heart rate and blood pressure
Heart rate and blood pressure will be measured follow-
ing a 15-min rest by a digital automatic sphygmoman-
ometer (Omron m6 ac; Omron Healthcare Co, Ltd,
Kyoto, Japan) at baseline and at the conclusion of the 3-
month intervention. The mean of two successive mea-
surements on each arm will be used.
Exercise capacity
For safety reasons, baseline recordings of exercise cap-
acity and muscle endurance will not be performed fol-
lowing the acute event, and absolute values of change in
exercise capacity after intervention can therefore not be
estimated. The following assessments are being used in
standard clinical care for all AMI patients in Sweden
and will be conducted at the 3-month follow-up.
Symptom-limited bicycle ergometer exercise test
The test-retest reliability of the symptom-limited bicycle
ergometer exercise test in patients with AMI included in
the SWEDEHEART registry is excellent [34]. This sub-
maximal exercise test will be performed on a bicycle erg-
ometer (Monark ProVO2, Monark, Varberg, Sweden)
according to a WHO protocol [35] and will be supervised
by qualified physical therapists blinded to the subject
intervention group. At rest, while sitting on the bicycle,
subjects will be informed of the test protocol and how to
rate their perceived exertion level according to the Borg
RPE-scale [36] and dyspnea or chest pain according to
Borg’s Category Ratio Scale (CR-10) [37]. Heart rate will
be registered at rest with a wireless heart rate sensor. Sys-
tolic and diastolic blood pressure will be measured in both
arms and reported for the arm with the highest value. Ini-
tial starting load, 25 W or 50 W, is based on the subject’s
exertion history, with an increased in workload of 25 W
every 4.5 min [38]. At 2 and 4 min of each workload, heart
rate and rating of Borg scales will be registered. At 3 min,
systolic blood pressure will be measured. The exercise test
will be discontinued upon reaching either 17 on Borg’s
RPE-scale or 7 on Borg’s CR-10 scale. Other criteria for
discontinuing the test are chest pain, drop in blood pres-
sure, failure to increase heart rate, and dizziness or other
discomfort. Exercise duration of the final increment will
be noted. If a subject does not complete the full 4.5 min of
the final increment, a corrected maximum workload will
be calculated using Strandell’s formula [39]: (submaxi-
mum workload) + (25 × n/4.5), where submaximal work-
load is the watt level prior to the termination step, and n
is the number of minutes completed at the watt level of
the final increment of exercise. Maximum oxygen uptake
(VO2max) at highest achieved workload will be estimated
with the Ekblom-Bak test (www.gih.se/ekblombaktest).
The dynamic unilateral heel-lift and unilateral shoulder-
flexion tests
These tests are designed to evaluate muscle endurance
and are commonly used in exercise-based cardiac
Table 3 Nutritional content of study products
Nutrition (g/100g) Dried bilberry drink Bioprocessed oat bran drink Bilberry + oat bran drink Reference drink
Energy (kcal/100g) 32.1 32.7 32.0 32.3
Fat 0.6 0.9 0.9 0.7
- Of which saturated fat 0.1 0.2 0.1 0.1
Protein 0.9 2.0 1.4 1.3
Carbohydrate 4.8 3.3 3.7 5.3
- Of which sugars 3.0 2.0 2.5 2.2
Dietary fiber 1.8 1.9 1.9 0.0
- Of which β-glucan 0.0 1.0 0.5 0.0
Salt 0.06 0.05 0.00 0.02
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rehabilitation settings and have excellent reliability for
patients with CVD [34, 40].
Physical activity scales
The Frändin/Grimby activity scale and the Haskell phys-
ical activity scale will be used to subjectively measure
physical activity level at baseline and follow-up [41, 42].
Food frequency questionnaire
All patients will complete a 132-item food frequency
questionnaire with questions related to daily food intake
and consumption of bilberries and oats before the study
[43]. Before and after the intervention, a full 3-day diet
record will be performed.
Register follow-up
At 1-year following randomization, we will exploratively
assess clinical endpoints in all randomized patients using
data from the Swedish Coronary Angiography and
Angioplasty Registry (SCAAR) with respect to death,
new AMI, and new unplanned revascularization.
Sample size calculation, data management, and statistical
analysis
To the best of our knowledge, no previous intervention
study of bilberry/oats with LDL cholesterol as an end-
point in AMI patients has been conducted. Required
sample size is calculated on the basis of bilberry-specific
interventions from four smaller randomized studies in
at-risk populations [18], from our pilot study [27], and
from the IMPROVE-IT trial [44], which found a clinic-
ally relevant LDL cholesterol-lowering effect of − 0.4
mmol/L when adding treatment with a non-statin agent
to standard statin lipid-lowering therapy after AMI. We
calculated that 189 subjects would be needed in each
study arm to provide 90% statistical power to detect a
0.4 mmol/L or greater reduction in LDL cholesterol in
the bilberry or the oat treatment group compared to the
reference, with a standard deviation of 1.1 mmol/L and a
Bonferroni corrected overall 5% two-sided significance
(Statistical Solutions Ltd, Cork, Ireland). The correction
is due to two primary hypotheses, (1) bilberry group vs.
reference and (2) oat group vs. reference. The same
number of participants will be enrolled in the combined
bilberry and oat treatment group, for a total of 756 pa-
tients in the study. In order to allow for an anticipated
dropout rate of ~ 15%, we plan to include 900 patients,
225 in each study arm.
Data will be transferred in coded form from the par-
ticipating centers to Örebro University Hospital, where
data management and statistical analyses will be per-
formed. All patients will be assigned an identifying num-
ber, recorded in the eCRF together with collected data.
A code list connected to patient study numbers with
individual Swedish resident personal identification num-
bers will be kept separately, and secured at the partici-
pating clinical centers. At completion of collection, a
database with data from the eCRF and national registers
will be established. The results will be analyzed accord-
ing to the intention-to-treat principle; that is, subjects
randomized to a given group will be followed and
assessed without regard to the diet intervention eventu-
ally received. A subject can withdraw from the study at
any time, if it is the wish of the subject, or if it is medic-
ally indicated, as judged by the investigator. Data col-
lected up to the end of follow-up will be used in the
final analysis of the study. If a subject wants to discon-
tinue the study participation, data collected until that
time point will be analyzed in the study. For the primary
outcome, on the original scale or log scale, as appropri-
ate, linear regression with pre-intervention to post-
intervention change as outcome, adjusted for the base-
line values, will be conducted. In cases of missing out-
come data, multiple imputation (MI) will be used.
Ordinal variables will be assessed with a χ2 test for trend
or the Mann-Whitney U test, and Pearson’s χ2 test or
Fisher’s exact test, as appropriate, will be used to evalu-
ate differences among proportions.
To assess compliance, we will compare polyphenolic
metabolites associated with bilberry and oat intake in
blood at baseline and at 3 months. For values that fall
below the limits of detection, an estimated concentration
of 50% of the detection limit will be used. Explorative
analyses of metabolome and microbiota (omics) data,
will be conducted at the Department of Biology and Bio-
logical Engineering at Chalmers University of Technol-
ogy. Instrumental analyses of microbiome and
untargeted metabolomics will generate raw data in the
range of terabytes. OMICs data will be analyzed at a ser-
ver dedicated for molecular studies linked to sensitive
personal data at The Swedish National Infrastructure for
Computing (SNIC) using primarily multivariate strat-
egies, incorporating unsupervised principal components
analysis–based strategies and supervised PLS and ran-
dom forest in-house strategies developed at Chalmers
University of Technology [45].
Administration of the trial
The steering committee, consisting of primary investiga-
tor Cecilia Bergh from the Clinical Epidemiology and
Biostatistics Unit, Örebro University Hospital and spon-
sor Ole Fröbert of the Department of Cardiology at
Örebro University Hospital, and Rikard Landberg from
the Department of Biology and Biological Engineering,
Food and Nutrition Science at Chalmers University of
Technology and David Erlinge of the department of Car-
diology at Lund University Hospital, is responsible for
planning and performance of the study. At the time of
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protocol submission, inclusion is planned at six national
sites: Sahlgrenska University Hospital Gothenburg,
Umeå University Hospital, Lund University Hospital,
Västerås general hospital, Karlstad general hospital, and
Örebro University Hospital, all with local site investiga-
tors. Newsletters including center recruitment status and
contact with local principal investigators will ensure
strategies for achieving adequate participant enrolment
to reach target sample size. Further sites may be added
during the study period to ensure inclusion of all 900
study subjects.
Study monitoring and data safety monitoring
The study will be monitored using SMART-TRIAL. Be-
fore beginning the clinical trial, all centers will have a
web-based meeting with presentation providing a de-
scription of the study, study procedures, and documen-
tation. During the study period, monitors will have
regular telephone contact with the participating depart-
ments to ensure the trial is conducted in compliance
with the protocol and applicable regulatory require-
ments. Monitoring will be conducted according to risk-
based monitoring and a study-specific plan by personnel
not otherwise involved in the study. An independent
Data Monitoring Committee will not be used as this is
considered a low-risk intervention.
Adherence to protocol will be continuously monitored
and the responsible centers notified of violations. Based
on previous research and our pilot study, we have no
reason to expect negative side effects or interactions
with bilberries or oats. Therefore, an interim safety ana-
lysis will not be conducted. Any side effects of the bil-
berry, oat or reference/placebo products will be
registered according to 7b World Allergy Organization
Subcutaneous Immunotherapy Systemic Reaction Grad-
ing System embedded in the eCRF.
Discussion
In the BIOAMI study, we will investigate the potential
cardiometabolic benefits of supplementation of standard
post-AMI treatment with daily bilberry and/or oat in-
take. We will assess whether beverages with dried bil-
berry and/or bioprocessed oat bran lower lipid levels,
reduce inflammation, and/or improve exercise capacity.
Given the significant ongoing CVD burden in patients
after AMI, there is a need for novel evidence-based
strategies for safe secondary prevention. Diet alteration
is a generally safe intervention, and international guide-
lines recommend diets high in fruits, vegetables, and
whole grains [10]. The source of the cardioprotective ef-
fects of specific diets such as the Mediterranean and
Nordic diet may be their high content of fruit, vegetable,
and whole grains — foods rich in bioactive compounds
and dietary fiber. Robust scientific evidence for clinical
effects of specific foods is warranted and for the role of
bioactive compounds that may mediate the effect. Bil-
berries and oats both contain phenolic compounds with
potential lipid-lowering and anti-inflammatory effects
[17, 23, 46]. The primary cholesterol-lowering effect of
oats has been attributed to the viscous soluble fiber
beta-glucans, and a cause-effect relationship has been
established [16]. Other potential CVD prevention prop-
erties of oats may involve anti-inflammatory and antioxi-
dant action as well as maintenance of endothelial
function [47]. This has been suggested by in vitro and
animal experiments with oat bran [48] as well as isolated
oat-specific polyphenols (avenanthramides) [49–51].
Polyphenols from bilberries may affect exercise toler-
ance [25, 26], and, in prospective studies, a high intake
of anthocyanins has been inversely associated with risk
of AMI [52, 53].
Some previous trials conducted in at-risk populations
have provided evidence of improved cardiovascular func-
tion following intervention with a Nordic diet that in-
cluded bilberries and oats [11–13] and from daily
bilberry consumption [54]. However, the potential bene-
fit of bilberry and oat intake in patients with manifest
CVD needs to be clarified in large clinical trials [15].
In contrast to previous smaller studies in at-risk popu-
lations, the proposed study is powered to evaluate clinic-
ally relevant effects on LDL cholesterol in patients
following overt AMI. In addition, we will use untargeted
metabolomics to detect potential biomarkers of re-
sponders and non-responders to the interventions and
characterize gut microbiome/diet interactions, as well as
to investigate how metabolic networks are affected by
the interventions.
All AMI patients in our pilot study received statin
therapy. Bilberry administration was initiated within 72
h of PCI during a vulnerable and critical clinical phase
[55, 56]. Despite statin treatment, we found significant
correlation of LDL cholesterol and oxidized LDL with
blood levels of anthocyanins after an 8-week interven-
tion, indicating a possible dose-response relationship of
anthocyanins in bilberries with cholesterol levels. The
lipid-lowering effect of bilberry could be partly explained
by the high anthocyanin content [57]. Oxidized LDL is
associated with all stages of atherosclerosis and with co-
morbidities linked to CVD, such as diabetes mellitus,
hypertension, and obesity [58]. We speculate that both
bilberries and oats could play a role in supplementing
medical therapy, but probably through different mecha-
nisms, showing potential for cumulative or synergistic
beneficial effects. Both bilberries and oats are natural
foods that have shown potential for CVD prevention
when provided separately, but their combined effects
have not been studied in clinical trials nor have effects
of bilberries or oats been studied in large populations
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with overt disease, as in this trial with 900 AMI patients.
A synergistic effect of oats and bilberries could suggest
development of novel cholesterol-lowering functional
foods as a potential cost-effective and safe dietary strat-
egy for reduction of cardiac risk after AMI.
In designing the intervention drinks, we faced a chal-
lenge regarding calorie intake. In order to balance the
four intervention drinks calorie-wise and to avoid high
contents of sucrose and starch content in the reference
product, we designed the combined bilberry/oat drink to
contain half the quantity of bilberry and oats in the sep-
arate drinks. Our study therefore does not fulfill 2 × 2
factorial design criteria, and this limits our ability to in-
vestigate possible interactions between bilberries and
oats without making assumptions about the linear dose-
response relationship.
Potential limitations also include non-adherence to the
dietary regimen. However, the intervention products, de-
veloped by food scientists representing both the aca-
demic and food science fields (Chalmers University of
Technology, Gothenburg, Sweden, and Glucanova, Lund,
Sweden, respectively), are shelf-stable ready-to-use bev-
erages with acceptable taste and freshness, containing
natural ingredients. In order to assess compliance, we
will compare polyphenolic metabolites in blood associ-
ated with bilberry and oat intake at baseline and at 3
months. Compliance with the intervention product in-
take will also be calculated from returned empty pack-
ages and unused drinks.
For safety reasons, baseline recordings of clinical exer-
cise and muscle tests will not be conducted; the absolute
values for changes in exercise capacity after AMI can
therefore not be estimated. However, subjectively
assessed physical activity will be evaluated at baseline
and at 3 months using validated questionnaires. Our
study is not powered to assess hard clinical endpoints
such as death, new AMI events, or new unplanned re-
vascularizations, but we will follow-up such events re-
ported in registries at 1 year following randomization, as
an exploratory analysis.
Current trial status
The trial was registered on ClinicalTrials.gov on August
8, 2018 (ID NCT03620266). Enrolment will begin in
September 2021 and is expected to continue for 2 years.
All study sites are prepared to start inclusion of patients
in 2021, with an amendment from the Ethical Review
Board approved for inclusion of Sahlgrenska University
Hospital Gothenburg and Karlstad general hospital. The
final results of the primary endpoint are projected for
August 2023. An open-label pilot study with 50 patients
was conducted in 2014/2015 and reported in 2018 [27],
and it resulted in some adjustments in the study proto-
col and design of the study with inclusion of oats and
two more study arms, and development of the pilot
product (dried bilberry powder), a liquid oat product,
their combination, and a reference/placebo product for
use in the intervention. Developed study products were
of importance for achieving high compliance to the diet-
ary regimen. The current protocol version is 2.0 and
dated December 20, 2019.
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